Phase II Study of a Temozolomide-Based Chemo-radiotherapy Regimen for High Risk Low-Grade Gliomas: Long-term Results of Radiation Therapy Oncology Group (RTOG) 0424

Minesh Mehta

Phase II Study of a Temozolomide-Based Chemo-radiotherapy Regimen for High Risk Low-Grade Gliomas: Long-term Results of Radiation Therapy Oncology Group (RTOG) 0424

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	International Journal of Radiation Oncology, Biology, Physics
Volume	107
State	Published - Jul 15 2020

Access to Document

ViewcontentFinal published version, 20.4 KBLicense: Unspecified

Cite this

@article{877feb9cbcf743f6bb90dfde03d4c0b7,

title = "Phase II Study of a Temozolomide-Based Chemo-radiotherapy Regimen for High Risk Low-Grade Gliomas: Long-term Results of Radiation Therapy Oncology Group (RTOG) 0424",

author = "Minesh Mehta",

note = "International Journal of Radiation Oncology, Biology, Physics (2020) 107(4):720-725",

year = "2020",

month = jul,

day = "15",

language = "American English",

volume = "107",

journal = "International Journal of Radiation Oncology, Biology, Physics",

}

TY - JOUR

T1 - Phase II Study of a Temozolomide-Based Chemo-radiotherapy Regimen for High Risk Low-Grade Gliomas: Long-term Results of Radiation Therapy Oncology Group (RTOG) 0424

AU - Mehta, Minesh

N1 - International Journal of Radiation Oncology, Biology, Physics (2020) 107(4):720-725

PY - 2020/7/15

Y1 - 2020/7/15

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/3558

M3 - Article

VL - 107

JO - International Journal of Radiation Oncology, Biology, Physics

JF - International Journal of Radiation Oncology, Biology, Physics

ER -

Phase II Study of a Temozolomide-Based Chemo-radiotherapy Regimen for High Risk Low-Grade Gliomas: Long-term Results of Radiation Therapy Oncology Group (RTOG) 0424

Access to Document

Other files and links

Cite this